论文部分内容阅读
成人急性淋巴细胞白血病(ALL)长期生存率仍不尽人意。作者采用改良的方案化疗,取得成人ALL中的最佳疗效。按FAB标准确诊的79例初治成人ALL患者,平均年龄27(15～60)岁。诱导化疗方案:长春新硷+强的松+天门冬酰胺酶及每周1次阿霉素和环磷酰胺连用3周。巩固化疗:柔红霉素
The long-term survival of adult acute lymphoblastic leukemia (ALL) remains unsatisfactory. The authors adopt a modified regimen of chemotherapy to achieve the best effect in adult ALL. According to FAB standard 79 cases of newly diagnosed adult patients with ALL, the average age of 27 (15 to 60) years old. Induction chemotherapy: vincristine + prednisone + asparaginase and 1 week weekly doxorubicin and cyclophosphamide for 3 weeks. Consolidation chemotherapy: daunorubicin